Fig. 1From: Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical studyaAll subjects were randomized at the beginning of the study to one of three avapritinib doses or placebo in Part 1BLU-285-2203 Part 1 study design. BSC best supportive care, GI gastrointestinal, ISM indolent systemic mastocytosis, PRO patient-reported outcome, RP2D recommended phase 2 dose, TSS total symptom score.Back to article page